Loading company…
Santhera Pharmaceuticals develops medicines for rare neuromuscular diseases.
Santhera Pharmaceuticals develops and commercializes medicines for rare neuromuscular diseases. Its products include AGAMREE® (vamorolone), which targets Duchenne muscular dystrophy. Founded in 2004 in Liestal, Switzerland, the company has completed 19 deals and raised CHF 88.50 million in a November 3, 2006 PIPE round led by Highbridge Capital Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in